| scholarly article | Q13442814 |
| P50 | author | Quentin J Sattentau | Q59822898 |
| Leopold Kong | Q61276651 | ||
| P2860 | cites work | Prediction methods for B-cell epitopes | Q51887353 |
| VaxGen vaccine trial fails the test but may offer insights | Q56933908 | ||
| AIDS groups applaud VaxGen despite vaccine trial results | Q56934323 | ||
| A sweet cleft in HIV's armour | Q59097964 | ||
| Limitations of the anti-idiotype strategy for an HIV vaccine | Q69744006 | ||
| Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines | Q71746910 | ||
| HIV-1 antibody--debris or virion? | Q73206011 | ||
| Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response | Q81367931 | ||
| Two meanings of reverse vaccinology and the empirical nature of vaccine science | Q84882734 | ||
| Computational Protein Design Using Flexible Backbone Remodeling and Resurfacing: Case Studies in Structure-Based Antigen Design | Q85244150 | ||
| Antibody vs. HIV in a clash of evolutionary titans | Q24536059 | ||
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals | Q24635002 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination | Q24676067 | ||
| Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design | Q24679395 | ||
| Vaccines: the Fourth Century | Q27490454 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Molecular architecture of native HIV-1 gp120 trimers | Q27651385 | ||
| Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 | Q27658449 | ||
| Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility | Q27658989 | ||
| Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 | Q27662167 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope | Q27664365 | ||
| A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity | Q27664589 | ||
| Elicitation of structure-specific antibodies by epitope scaffolds | Q27664711 | ||
| Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 | Q27666407 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold | Q27675190 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein | Q28140278 | ||
| Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. | Q28217208 | ||
| Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41 | Q28236154 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Structure of an unliganded simian immunodeficiency virus gp120 core | Q29616089 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Evolutionary and immunological implications of contemporary HIV-1 variation. | Q30329205 | ||
| Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. | Q30355613 | ||
| The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. | Q30367176 | ||
| Vaccine Design for CD8 T Lymphocyte Responses | Q30411492 | ||
| Correlation between segmental mobility and the location of antigenic determinants in proteins | Q30412108 | ||
| Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. | Q30681068 | ||
| Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 | Q30701127 | ||
| Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes | Q31143023 | ||
| Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries | Q32145824 | ||
| Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation | Q33346236 | ||
| Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope | Q33417195 | ||
| Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 | Q33571605 | ||
| Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein | Q33571825 | ||
| Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. | Q33636347 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Glycoproteins: glycan presentation and protein-fold stability | Q33699059 | ||
| Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity | Q33782556 | ||
| Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers | Q33836042 | ||
| Rational antibody-based HIV-1 vaccine design: current approaches and future directions | Q33937285 | ||
| Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies | Q34006748 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies | Q34094476 | ||
| Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity | Q34175370 | ||
| Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. | Q34204047 | ||
| Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine | Q34225659 | ||
| Scaffolding to build a rational vaccine design strategy | Q34241394 | ||
| Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants | Q34302085 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection | Q34317025 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope | Q34348303 | ||
| Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots | Q34355430 | ||
| Effects of glycosylation on peptide conformation: a synergistic experimental and computational study. | Q34418726 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Antigenicity and immunogenicity of synthetic peptides | Q34535909 | ||
| Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio | Q34583767 | ||
| An HIV vaccine--evolving concepts | Q34629012 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| Is developing an HIV-1 vaccine possible? | Q35043547 | ||
| Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures | Q35105223 | ||
| Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies | Q35116581 | ||
| Progress in the rational design of an AIDS vaccine | Q35137125 | ||
| Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated | Q35441583 | ||
| Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. | Q35603504 | ||
| Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization | Q35660279 | ||
| Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles | Q35704086 | ||
| Identifying epitopes of HIV-1 that induce protective antibodies | Q35708836 | ||
| AIDSVAX VaxGen. | Q35713970 | ||
| Live attenuated HIV vaccines: pitfalls and prospects | Q35748470 | ||
| V3: HIV's switch-hitter | Q36051661 | ||
| Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors | Q36250468 | ||
| Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer | Q36365085 | ||
| Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses | Q36626160 | ||
| Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. | Q36627098 | ||
| Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. | Q36634499 | ||
| Identification of HIV Vaccine Candidate Peptides by Screening Random Phage Epitope Libraries | Q36695492 | ||
| A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120 | Q36748055 | ||
| Exploiting the defensive sugars of HIV-1 for drug and vaccine design | Q36802333 | ||
| Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies | Q37033269 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| COBEpro: a novel system for predicting continuous B-cell epitopes | Q37101584 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 | Q37596552 | ||
| Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope | Q37596817 | ||
| Immunogenicity of HIV-1 envelope glycoprotein oligomers | Q37667740 | ||
| Challenges for structure-based HIV vaccine design | Q37667763 | ||
| The role of antibodies in HIV vaccines | Q37700725 | ||
| Limitations to the structure‐based design of HIV‐1 vaccine immunogens | Q37910841 | ||
| Polyreactive antibodies in adaptive immune responses to viruses | Q37951868 | ||
| The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator. | Q38296838 | ||
| Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160. | Q38309325 | ||
| Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. | Q39457063 | ||
| The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors | Q39597685 | ||
| The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region | Q39602963 | ||
| Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization | Q39723388 | ||
| Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex | Q39878965 | ||
| Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. | Q40011566 | ||
| Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization | Q40059024 | ||
| Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5. | Q40225027 | ||
| The rational design of an AIDS vaccine | Q40348550 | ||
| Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis | Q40397998 | ||
| Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. | Q40626990 | ||
| Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein | Q40937092 | ||
| Affinity Dependence of the B Cell Response to Antigen: A Threshold, a Ceiling, and the Importance of Off-Rate | Q41027647 | ||
| Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. | Q41103077 | ||
| The influence of virus structure on antibody responses and virus serotype formation | Q41305357 | ||
| Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker | Q41493875 | ||
| Dissociation of gp120 from HIV-1 virions induced by soluble CD4. | Q41714439 | ||
| Immunogenicity of the outer domain of a HIV-1 clade C gp120. | Q41961460 | ||
| Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment | Q42039880 | ||
| Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans | Q42265635 | ||
| Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. | Q44572417 | ||
| Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. | Q44599903 | ||
| Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies | Q44646864 | ||
| Vaccinology: precisely tuned antibodies nab HIV. | Q45138465 | ||
| Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. | Q45149860 | ||
| A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. | Q45409784 | ||
| Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer | Q45736020 | ||
| Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev | Q45771982 | ||
| Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope | Q46331384 | ||
| A role for carbohydrates in immune evasion in AIDS | Q47982875 | ||
| What is a B-cell epitope? | Q47983504 | ||
| P921 | main subject | HIV | Q15787 |
| vaccine engineering | Q14861085 | ||
| P304 | page(s) | 3 | |
| P577 | publication date | 2012-03-22 | |
| P1433 | published in | Journal of AIDS & clinical research | Q27723591 |
| P1476 | title | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design | |
| P478 | volume | S8 |
| Q26829865 | A Blueprint for HIV Vaccine Discovery |
| Q40245017 | An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques |
| Q38283531 | An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine |
| Q35580892 | Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate |
| Q34022578 | Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q33955745 | Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein |
| Q46683819 | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning |
| Q36434196 | Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens |
| Q36079024 | Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising |
| Q37042563 | Development of prophylactic vaccines against HIV-1. |
| Q27644515 | Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies |
| Q38581943 | Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens |
| Q30391094 | Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity. |
| Q27000480 | HIV‐1 neutralizing antibodies: understanding nature's pathways |
| Q37045832 | Human Immunodeficiency Virus (HIV). |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q89939962 | Level of Knowledge About Prevention of Mother-to-Child Transmission of HIV Option B+ and Associated Factors Among ANC Clients in Kombolcha Town, South Wollo Amhara Regional State, Ethiopia, 2017 |
| Q40589505 | Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice |
| Q30353580 | Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 |
| Q50011228 | Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies. |
| Q33451308 | Sexual Preferences and Presentation on Geosocial Networking Apps by Indian Men Who Have Sex With Men in Maharashtra |
| Q30490942 | Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. |
| Q57093739 | Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies |
| Q28071559 | Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory |
| Q35926734 | The challenges of modelling antibody repertoire dynamics in HIV infection |
Search more.